More MS news articles for Jan 2002

Biogen to Settle Patent Litigation with Berlex; Settlement Subject to Pending U.S. Court of Appeals Decision

http://news.ft.com/ft/gx.cgi/ftc?pagename=View&c=Article&cid=FT3KN16NUWC

Jan 24, 2002
PR Newswire - USA;

Berlex Laboratories, the U.S. affiliate of Schering AG Germany said today that it has reached a settlement with Biogen Corporation in connection with infringement litigation over Berlex's patents covering the manufacture of Biogen's Avonex(R).

Subject to the outcome of a pending appeal, the settlement preserves Berlex's and the Schering Group's upside potential to leverage the asset value of its intellectual property. Biogen will initially pay Berlex $20 million. Depending on the nature of the ruling by the U.S. Court Appeals, Berlex and the Schering Group may receive a second payment of Berlex of either $55 million or $230 million in return for a license to the patents. These payments will be shared with Stanford University and Chiron Corporation according to existing contractual arrangements.

The proprietary technology concerns the production of human beta interferon in mammalian Chinese hamster ovary (CHO) cells and the manufacture, use, and sale in the United States. Berlex markets the pioneering treatment for multiple sclerosis, Betaseron(R).

Berlex Laboratories is the U.S. operating affiliate of Schering AG Germany , a biopharmaceuticals company, and the world leader in diagnostics/imaging, womens health, and the maker of specialty medicines for neurology, cancer, cardiovascular disorders and dermatology.

Contact: Media, Jane A. Kramer, +1-973-487-2246, or home, +1-973-331-7997, or Investors, Joanne Marion, +1-973-487-2164, both of Berlex Laboratories
 

World Reporter All Material Subject to Copyright